Navigation Links
SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
Date:11/17/2009

MUMBAI, India, Nov. 17 /PRNewswire/ -- SIRO Clinpharm, a global Contract Research Organization (CRO) with bases in India, US, Europe and Israel today announced their alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France.

Mediscis is an established expert in GCP compliant early phase drug development services including clinical trials and bioanalytics. SIRO offers expertise across all study phases for the pharmaceutical and biotech industry.

"This will be an important collaboration for both the parties as they stand to gain access to each others' core competencies," said Scott Spector, President, Strategic Operations, Europe. "This alliance will allow us to provide additional services to our global clients to support their clinical development plans."

"Following the acquisition of Omega Mediation Clinical Research Services, SIRO was able to establish a footprint in the European clinical research market. We envision becoming a leading drug development solutions provider by delivering compelling value propositions to the global healthcare industry. From this alliance, we are glad that we can offer a larger array of services to our global clientele and move closer to our vision," said Dr. Chetan Tamhankar, Chief Operating Officer of SIRO Clinpharm.

About SIRO:

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the Pharmaceutical, Biotechnology and Medical Devices sectors in compliance with International Standards. SIRO is one of the first CROs founded in India and caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Europe in Germany, Romania, Estonia, Greece and Czech Republic.

For more information visit our website at www.siroclinpharm.com.

SOURCE SIRO Clinpharm


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
2. SIRO Clinpharm and CambReg Ltd Strategic Alliance to Offer Regulatory Services in Europe
3. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
4. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
8. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... IL (PRWEB) , ... February 24, 2017 , ... The ... the 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. ... Choice will be showcased and the winner revealed at the 31st annual iaedp Symposium, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will ... the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our ... This year’s Bunkum winner is the Center for American Progress (CAP), for its report, ...
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... the first two episodes of WE TV’s “Mama June: From Not to Hot,” which ... of TV notable, “Mama” June Shannon, known to millions from the 2012 reality television ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... will host a diverse symposium on “Doping in Sport: How the ... Sheppard Mullin Richter & Hampton LLP. The symposium will be held at Pepperdine ...
Breaking Medicine News(10 mins):